Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) vs Liminatus Pharma, Inc. Class A Common Stock (LIMN)
A side-by-side comparison of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares and Liminatus Pharma, Inc. Class A Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$2.12HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$3.85HealthcareDelayed quote: Oct 6, 2026, 12:43 PM EDT
Total return — CUPR vs LIMN
growth of $100 · dividends reinvested · last 1yCUPR -93.8% (-93.8%/yr)LIMN -98.4% (-98.4%/yr)CUPR compounded faster over this window
CUPR LIMN
CUPR vs LIMN: by the numbers
- •CUPR is the larger company ($6M vs $5M market cap).
- •Both run net losses; LIMN's is the smaller (0.00% vs -9366.75% net margin).
Metrics side by side
Valuation
| Metric | CUPR | LIMN |
|---|---|---|
| P/B ratio | 1.45 | 17.18 |
Profitability
| Metric | CUPR | LIMN |
|---|---|---|
| Gross margin | -1.29% | 0.00% |
| Operating margin | -9154.62% | 0.00% |
| Net margin | -9366.75% | 0.00% |
| ROE | -92.44% | -4165.92% |
| ROIC | -84.15% | -225.12% |
Go deeper
Dig into the metrics
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares ROELiminatus Pharma, Inc. Class A Common Stock ROECuprina Holdings (Cayman) Limited Class A Ordinary Shares operating marginLiminatus Pharma, Inc. Class A Common Stock operating marginCuprina Holdings (Cayman) Limited Class A Ordinary Shares revenue growthLiminatus Pharma, Inc. Class A Common Stock revenue growthCuprina Holdings (Cayman) Limited Class A Ordinary Shares free cash flowLiminatus Pharma, Inc. Class A Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.